ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / STXS / news
NRXS (36) HYPR (38) VANI (28) OM (34) ⌘ Pro Terminal →

Why STXS Stock surged +2.03% Today — RQD Quant Desk Flash

$0.88 +2.03% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.88

Stereotaxis Inc. (STXS) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $86.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STXS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Stereotaxis Inc. (NYSE: STXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $0.88 (+2.03% 1D, market cap $86.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STXS ranks #961 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STXS compare to NRXS and HYPR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), STXS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 52.7%, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $89.5M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STXS?
▼

Per STXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001289340), Stereotaxis Inc. generated $32.4M in revenue (+20.3% YoY), -$21.6M in net income, and -$13.7M in free cash flow against $52.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.88 (+0.18%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510022
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (3)SEC (8)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.9% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE STXS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STXS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (22/100 Composite)
🔍 WHY STXS SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$1.06-5.7% Next Q
Q2 (-2Q)
27
Grade E$1.00+3% Next Q
Q3 (-1Q)
25
Grade E$1.03-14.6% Next Q
Current
22
Grade E$0.88-11.4% Hist 90D α
Trajectory: E (30) → E (22)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STXS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STXS currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.92) forces dealer call-delta covering toward $3.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STXS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 22%NO 78%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why STXS Stock surged +2.03% Today — RQD Quant Desk Flash

Stereotaxis Inc. (STXS) surged +2.03% to $0.88, trading at 3% of its 52-week range ($0.81 – $2.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 3% of its 52-week range ($0.81 – $2.93) with RSI-14 at 27.4 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.88 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52.7% gross margin and $0 annual free cash flow.
Live STXS Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STXS)

  • ✓Walkthrough of STXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
STXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.68%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.91H $0.91L $0.86C $0.88VOL 1.44M
RES: $1.12SUP: $0.80SMA50: $1.20SMA200: $1.69
$2.55$2.08$1.61$1.14$0.66RES $1.12SUP $0.80$0.882026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STXS Butterfly Map → + Track STXS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +20.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on STXS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STXS)

Health Care Rank #961 of 1015 ⚔️ NRXS vs STXS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STXS vs. NRXS, HYPR, VANI, OM)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Stereotaxis Inc. (STXS) ranks #961 by composite RQD confidence (22/100, grade E) and #673 by equity capitalization ($86.4M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with STXS at 22/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
STXS ACTIVE
Stereotaxis Inc.
E 22/100 — 52.7% -35.0% +2.03% $86.4M Benchmark Subject
NRXS
Neuraxis Inc.
D- 36/100 — 84.2% -35.0% -7.43% $89.5M /nrxs-vs-stxs →
HYPR
Hyperfine Inc. (Class A)
D- 38/100 — 49.8% -35.0% +0.99% $76.1M /hypr-vs-stxs →
VANI
Vivani Medical Inc.
E 28/100 3.9x — -35.0% 0.00% $98.3M /vani-vs-stxs →
OM
Outset Medical Inc.
E 34/100 — 39.1% -28.0% -0.25% $75.8M /om-vs-stxs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001289340 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stereotaxis Inc. (STXS) reported GAAP revenue of $32.4M (+20.3% vs. FY2024 revenue of $26.9M , and +20.9% cumulative change since FY2023) , GAAP net income of -$21.6M, operating cash flow of -$13.7M, and free cash flow of -$13.7M (-61.1% YoY). On the balance sheet, STXS closed FY2025 with $52.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $32.4M -$21.6M -$13.7M -$13.7M $52.3M —
FY2024 (FY) 2024-12-31 $26.9M -$24.0M -$8.5M -$8.5M $46.7M —
FY2023 (FY) 2023-12-31 $26.8M -$20.7M -$9.1M -$9.1M — —

3. STXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Stereotaxis Inc. (NYSE: STXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $0.88 (+2.03% 1D, market cap $86.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STXS ranks #961 in composite RQD confidence.

How does STXS compare to NRXS and HYPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), STXS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 52.7%, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $89.5M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for STXS?

Per STXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001289340), Stereotaxis Inc. generated $32.4M in revenue (+20.3% YoY), -$21.6M in net income, and -$13.7M in free cash flow against $52.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is STXS trading relative to its 50-day, 200-day, and 52-week technical levels?

STXS last traded at $0.88 (+2.03% on volume of 532,674 shares), positioning the stock -26.67% below its 50-day simple moving average ($1.20) and -47.93% below its 200-day simple moving average ($1.69). Across its 52-week range of $0.81 to $2.93, STXS sits at the 3.3% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).

Direct Sub-Reports: STXS RQD Cockpit STXS 12M Forecast STXS Earnings & Move STXS Dividends & DRIP STXS Insiders & 13F STXS Whale Options STXS Profit Sankey STXS News & Why
ROARABLE RATING BRIEF • RQD 22/100 (E) ✓ SEC XBRL & RQD VERIFIED

STXS — Stereotaxis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Stereotaxis Inc. (STXS) earns a live Roarable RQD composite score of 22/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.88 (+2.03% 1D, market capitalization $86.4M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 52.7%, operating margin of -60.0%, and free cash flow yield of -15.01%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Stereotaxis Inc. (STXS) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Its market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Stereotaxis Inc. (STXS) reported $32.4M in annual revenue (up from $26.9M in FY2024, +20.3% YoY) and -$21.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.8M revenue, -$20.7M net income) through FY2025, STXS scaled operating cash flow to -$13.7M and free cash flow to -$13.7M, backed by $52.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 22/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -15.01% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.81 – $2.93 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), STXS carries a macro regime beta of 1.00 and gross margin of 52.7%.

  • Key Question #1: Can STXS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $32.4M and free cash flow of -$13.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is STXS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

STXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Stereotaxis Inc. (STXS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STXS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STXS Bull vs. Bear Conversation Board — What's Your Call at $0.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STXS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on STXS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.03 (+19.8%)
📌 Pinned Debate

Revenue grew from $26.9M in FY 2024 to $32.4M in FY 2025 and reported cash rose to $13.4M, with a 0.5 Debt/Equity ratio and an Altman Z

Long STXS at $0.86 targeting $1.03. Revenue grew from $26.9M in FY 2024 to $32.4M in FY 2025 and reported cash rose to $13.4M, with a 0.5 Debt/Equity ratio and an Altman Z-Score of 2.5 supporting the balance sheet pillar.. Institutional whale score is 3/20 and the risk/reward vs. the $0.81 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 22/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.86 and keeping dry powder in case we test $0.80.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.71 (-17.4%)
Spot @ $0.86

ROIC of -35%, an FCF yield of -15.01%, and operating margin of -60% show the business is not generating cash returns, pulling the RQD s

I respect the product at Stereotaxis Inc., but the stock at $0.86 is a different story. ROIC of -35%, an FCF yield of -15.01%, and operating margin of -60% show the business is not generating cash returns, pulling the RQD score to 22 and grade E.. FCF yield is -15.01% and RQD sits at 22/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%